MovDisordV3, PascalFrancis, Corpus, bibRecord, 001B86

Effect of amantadine in essential tremor : A randomized, placebo-controlled trial

Identifieur interne : 001B86 ( PascalFrancis/Corpus ); précédent : 001B85; suivant : 001B87

Effect of amantadine in essential tremor : A randomized, placebo-controlled trial

Auteurs : Alexandre Gironell ; Jaime Kulisevsky ; Berta Pascual-Sedano ; David Flamarich

Source :

Movement disorders [ 0885-3185 ] ; 2006.

RBID : Pascal:06-0244403

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Tremblement, Amantadine, Placebo, Accélérométrie.

English descriptors

KwdEn :
- Accelerometry, Amantadine, Nervous system diseases, Placebo, Tremor.

Abstract

There is a need for new medication for essential tremor (ET). Preliminary evidence suggests that amantadine may be effective in the treatment of ET. We studied the effects of amantadine in a double-blind, cross-over, placebo-controlled trial in ET patients. Sixteen patients with ET received amantadine 100 mg b.i.d. and placebo for 15 days, with a 1-week wash-out period between treatments. Major evaluation outcomes consisted of a tremor clinical rating scale, accelerometric recordings, and a self-reported disability scale obtained before drug intake and on study days 1 and 15 of each treatment period. A two-way repeated measures analysis of variance (treatment, time) was applied. Any P value < 0.05 was considered significant. On day 15, amantadine did not demonstrate any significant efficacy in reducing tremor with respect to baseline in any tremor measures. An increase in postural tremor as an adverse effect of amantadine was referred by 37.5% of patients. Results from the present trial indicate amantadine at 100 mg b.i.d. is not effective as a treatment for ET.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 21`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 Effect of amantadine in essential tremor : A randomized, placebo-controlled trial`
A11	`01`	`1`		`@1 GIRONELL (Alexandre)`
A11	`02`	`1`		`@1 KULISEVSKY (Jaime)`
A11	`03`	`1`		`@1 PASCUAL-SEDANO (Berta)`
A11	`04`	`1`		`@1 FLAMARICH (David)`
A14	`01`			`@1 Movement Disorders Unit, Department of Neurology, Sant Pau Hospital, Autonomous University of Barcelona @2 Catalonia @3 ESP @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut.`
A20				`@1 441-445`
A21				`@1 2006`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000156737350010`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 26 ref.`
A47	`01`	`1`		`@0 06-0244403`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 There is a need for new medication for essential tremor (ET). Preliminary evidence suggests that amantadine may be effective in the treatment of ET. We studied the effects of amantadine in a double-blind, cross-over, placebo-controlled trial in ET patients. Sixteen patients with ET received amantadine 100 mg b.i.d. and placebo for 15 days, with a 1-week wash-out period between treatments. Major evaluation outcomes consisted of a tremor clinical rating scale, accelerometric recordings, and a self-reported disability scale obtained before drug intake and on study days 1 and 15 of each treatment period. A two-way repeated measures analysis of variance (treatment, time) was applied. Any P value < 0.05 was considered significant. On day 15, amantadine did not demonstrate any significant efficacy in reducing tremor with respect to baseline in any tremor measures. An increase in postural tremor as an adverse effect of amantadine was referred by 37.5% of patients. Results from the present trial indicate amantadine at 100 mg b.i.d. is not effective as a treatment for ET.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B02Q`
C02	`03`	`X`		`@0 002B17F`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Tremblement @5 02`
C03	`02`	`X`	`ENG`	`@0 Tremor @5 02`
C03	`02`	`X`	`SPA`	`@0 Temblor @5 02`
C03	`03`	`X`	`FRE`	`@0 Amantadine @2 NK @2 FR @5 09`
C03	`03`	`X`	`ENG`	`@0 Amantadine @2 NK @2 FR @5 09`
C03	`03`	`X`	`SPA`	`@0 Amantadina @2 NK @2 FR @5 09`
C03	`04`	`X`	`FRE`	`@0 Placebo @5 10`
C03	`04`	`X`	`ENG`	`@0 Placebo @5 10`
C03	`04`	`X`	`SPA`	`@0 Placebo @5 10`
C03	`05`	`X`	`FRE`	`@0 Accélérométrie @5 11`
C03	`05`	`X`	`ENG`	`@0 Accelerometry @5 11`
C03	`05`	`X`	`SPA`	`@0 Accelerometría @5 11`
C07	`01`	`X`	`FRE`	`@0 Mouvement involontaire @5 37`
C07	`01`	`X`	`ENG`	`@0 Involuntary movement @5 37`
C07	`01`	`X`	`SPA`	`@0 Movimiento involuntario @5 37`
C07	`02`	`X`	`FRE`	`@0 Trouble neurologique @5 38`
C07	`02`	`X`	`ENG`	`@0 Neurological disorder @5 38`
C07	`02`	`X`	`SPA`	`@0 Trastorno neurológico @5 38`
N21				`@1 156`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 06-0244403 INIST
ET :	Effect of amantadine in essential tremor : A randomized, placebo-controlled trial
AU :	GIRONELL (Alexandre); KULISEVSKY (Jaime); PASCUAL-SEDANO (Berta); FLAMARICH (David)
AF :	Movement Disorders Unit, Department of Neurology, Sant Pau Hospital, Autonomous University of Barcelona/Catalonia/Espagne (1 aut., 2 aut., 3 aut., 4 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2006; Vol. 21; No. 4; Pp. 441-445; Bibl. 26 ref.
LA :	Anglais
EA :	There is a need for new medication for essential tremor (ET). Preliminary evidence suggests that amantadine may be effective in the treatment of ET. We studied the effects of amantadine in a double-blind, cross-over, placebo-controlled trial in ET patients. Sixteen patients with ET received amantadine 100 mg b.i.d. and placebo for 15 days, with a 1-week wash-out period between treatments. Major evaluation outcomes consisted of a tremor clinical rating scale, accelerometric recordings, and a self-reported disability scale obtained before drug intake and on study days 1 and 15 of each treatment period. A two-way repeated measures analysis of variance (treatment, time) was applied. Any P value < 0.05 was considered significant. On day 15, amantadine did not demonstrate any significant efficacy in reducing tremor with respect to baseline in any tremor measures. An increase in postural tremor as an adverse effect of amantadine was referred by 37.5% of patients. Results from the present trial indicate amantadine at 100 mg b.i.d. is not effective as a treatment for ET.
CC :	002B17; 002B02Q; 002B17F
FD :	Système nerveux pathologie; Tremblement; Amantadine; Placebo; Accélérométrie
FG :	Mouvement involontaire; Trouble neurologique
ED :	Nervous system diseases; Tremor; Amantadine; Placebo; Accelerometry
EG :	Involuntary movement; Neurological disorder
SD :	Sistema nervioso patología; Temblor; Amantadina; Placebo; Accelerometría
LO :	INIST-20953.354000156737350010
ID :	06-0244403

Links to Exploration step

Pascal:06-0244403

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effect of amantadine in essential tremor : A randomized, placebo-controlled trial</title>
<author><name sortKey="Gironell, Alexandre" sort="Gironell, Alexandre" uniqKey="Gironell A" first="Alexandre" last="Gironell">Alexandre Gironell</name>
<affiliation><inist:fA14 i1="01"><s1>Movement Disorders Unit, Department of Neurology, Sant Pau Hospital, Autonomous University of Barcelona</s1>
<s2>Catalonia</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name>
<affiliation><inist:fA14 i1="01"><s1>Movement Disorders Unit, Department of Neurology, Sant Pau Hospital, Autonomous University of Barcelona</s1>
<s2>Catalonia</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pascual Sedano, Berta" sort="Pascual Sedano, Berta" uniqKey="Pascual Sedano B" first="Berta" last="Pascual-Sedano">Berta Pascual-Sedano</name>
<affiliation><inist:fA14 i1="01"><s1>Movement Disorders Unit, Department of Neurology, Sant Pau Hospital, Autonomous University of Barcelona</s1>
<s2>Catalonia</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Flamarich, David" sort="Flamarich, David" uniqKey="Flamarich D" first="David" last="Flamarich">David Flamarich</name>
<affiliation><inist:fA14 i1="01"><s1>Movement Disorders Unit, Department of Neurology, Sant Pau Hospital, Autonomous University of Barcelona</s1>
<s2>Catalonia</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0244403</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0244403 INIST</idno>
<idno type="RBID">Pascal:06-0244403</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001B86</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effect of amantadine in essential tremor : A randomized, placebo-controlled trial</title>
<author><name sortKey="Gironell, Alexandre" sort="Gironell, Alexandre" uniqKey="Gironell A" first="Alexandre" last="Gironell">Alexandre Gironell</name>
<affiliation><inist:fA14 i1="01"><s1>Movement Disorders Unit, Department of Neurology, Sant Pau Hospital, Autonomous University of Barcelona</s1>
<s2>Catalonia</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name>
<affiliation><inist:fA14 i1="01"><s1>Movement Disorders Unit, Department of Neurology, Sant Pau Hospital, Autonomous University of Barcelona</s1>
<s2>Catalonia</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pascual Sedano, Berta" sort="Pascual Sedano, Berta" uniqKey="Pascual Sedano B" first="Berta" last="Pascual-Sedano">Berta Pascual-Sedano</name>
<affiliation><inist:fA14 i1="01"><s1>Movement Disorders Unit, Department of Neurology, Sant Pau Hospital, Autonomous University of Barcelona</s1>
<s2>Catalonia</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Flamarich, David" sort="Flamarich, David" uniqKey="Flamarich D" first="David" last="Flamarich">David Flamarich</name>
<affiliation><inist:fA14 i1="01"><s1>Movement Disorders Unit, Department of Neurology, Sant Pau Hospital, Autonomous University of Barcelona</s1>
<s2>Catalonia</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Accelerometry</term>
<term>Amantadine</term>
<term>Nervous system diseases</term>
<term>Placebo</term>
<term>Tremor</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Tremblement</term>
<term>Amantadine</term>
<term>Placebo</term>
<term>Accélérométrie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">There is a need for new medication for essential tremor (ET). Preliminary evidence suggests that amantadine may be effective in the treatment of ET. We studied the effects of amantadine in a double-blind, cross-over, placebo-controlled trial in ET patients. Sixteen patients with ET received amantadine 100 mg b.i.d. and placebo for 15 days, with a 1-week wash-out period between treatments. Major evaluation outcomes consisted of a tremor clinical rating scale, accelerometric recordings, and a self-reported disability scale obtained before drug intake and on study days 1 and 15 of each treatment period. A two-way repeated measures analysis of variance (treatment, time) was applied. Any P value < 0.05 was considered significant. On day 15, amantadine did not demonstrate any significant efficacy in reducing tremor with respect to baseline in any tremor measures. An increase in postural tremor as an adverse effect of amantadine was referred by 37.5% of patients. Results from the present trial indicate amantadine at 100 mg b.i.d. is not effective as a treatment for ET.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>21</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Effect of amantadine in essential tremor : A randomized, placebo-controlled trial</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>GIRONELL (Alexandre)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>KULISEVSKY (Jaime)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>PASCUAL-SEDANO (Berta)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>FLAMARICH (David)</s1>
</fA11>
<fA14 i1="01"><s1>Movement Disorders Unit, Department of Neurology, Sant Pau Hospital, Autonomous University of Barcelona</s1>
<s2>Catalonia</s2>
<s3>ESP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>441-445</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000156737350010</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>26 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0244403</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>There is a need for new medication for essential tremor (ET). Preliminary evidence suggests that amantadine may be effective in the treatment of ET. We studied the effects of amantadine in a double-blind, cross-over, placebo-controlled trial in ET patients. Sixteen patients with ET received amantadine 100 mg b.i.d. and placebo for 15 days, with a 1-week wash-out period between treatments. Major evaluation outcomes consisted of a tremor clinical rating scale, accelerometric recordings, and a self-reported disability scale obtained before drug intake and on study days 1 and 15 of each treatment period. A two-way repeated measures analysis of variance (treatment, time) was applied. Any P value < 0.05 was considered significant. On day 15, amantadine did not demonstrate any significant efficacy in reducing tremor with respect to baseline in any tremor measures. An increase in postural tremor as an adverse effect of amantadine was referred by 37.5% of patients. Results from the present trial indicate amantadine at 100 mg b.i.d. is not effective as a treatment for ET.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B02Q</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17F</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Tremblement</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Tremor</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Temblor</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Amantadine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Amantadine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Amantadina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Placebo</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Placebo</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Placebo</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Accélérométrie</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Accelerometry</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Accelerometría</s0>
<s5>11</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>38</s5>
</fC07>
<fN21><s1>156</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 06-0244403 INIST</NO>
<ET>Effect of amantadine in essential tremor : A randomized, placebo-controlled trial</ET>
<AU>GIRONELL (Alexandre); KULISEVSKY (Jaime); PASCUAL-SEDANO (Berta); FLAMARICH (David)</AU>
<AF>Movement Disorders Unit, Department of Neurology, Sant Pau Hospital, Autonomous University of Barcelona/Catalonia/Espagne (1 aut., 2 aut., 3 aut., 4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2006; Vol. 21; No. 4; Pp. 441-445; Bibl. 26 ref.</SO>
<LA>Anglais</LA>
<EA>There is a need for new medication for essential tremor (ET). Preliminary evidence suggests that amantadine may be effective in the treatment of ET. We studied the effects of amantadine in a double-blind, cross-over, placebo-controlled trial in ET patients. Sixteen patients with ET received amantadine 100 mg b.i.d. and placebo for 15 days, with a 1-week wash-out period between treatments. Major evaluation outcomes consisted of a tremor clinical rating scale, accelerometric recordings, and a self-reported disability scale obtained before drug intake and on study days 1 and 15 of each treatment period. A two-way repeated measures analysis of variance (treatment, time) was applied. Any P value < 0.05 was considered significant. On day 15, amantadine did not demonstrate any significant efficacy in reducing tremor with respect to baseline in any tremor measures. An increase in postural tremor as an adverse effect of amantadine was referred by 37.5% of patients. Results from the present trial indicate amantadine at 100 mg b.i.d. is not effective as a treatment for ET.</EA>
<CC>002B17; 002B02Q; 002B17F</CC>
<FD>Système nerveux pathologie; Tremblement; Amantadine; Placebo; Accélérométrie</FD>
<FG>Mouvement involontaire; Trouble neurologique</FG>
<ED>Nervous system diseases; Tremor; Amantadine; Placebo; Accelerometry</ED>
<EG>Involuntary movement; Neurological disorder</EG>
<SD>Sistema nervioso patología; Temblor; Amantadina; Placebo; Accelerometría</SD>
<LO>INIST-20953.354000156737350010</LO>
<ID>06-0244403</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B86 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001B86 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:06-0244403
   |texte=   Effect of amantadine in essential tremor : A randomized, placebo-controlled trial
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Effect of amantadine in essential tremor : A randomized, placebo-controlled trial

Effect of amantadine in essential tremor : A randomized, placebo-controlled trial

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri